Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A dilated cardiomyopathy that is characterized by neonatal onset of severe cardiomyopathy, with rapid progression to cardiac decompensation and death unless the patient undergoes heart transplantation and that has material basis in homozygous or compound heterozygous mutation in the RPL3L gene on chromosome 16p13.
Features include always present findings: Interstitial cardiac fibrosis, Reduced left ventricular ejection fraction, Perinuclear cardiomyocyte vacuolization, and Enlarged and weakened heart (dilated cardiomyopathy); and common findings: High blood pressure in lung arteries (pulmonary arterial hypertension), Tricuspid regurgitation, and Mitral regurgitation. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 7 |
RPL3L function has not been fully characterized.
Cardiomyopathy, dilated, 2D has been associated with mutations in the RPL3L gene on chromosome 16.
Genetic testing for RPL3L is available. Testing is considered supportive for diagnosis.
Biomarker and diagnostic research for cardiomyopathy, dilated, 2D has been reported in the published literature.
Phenotype severity distribution: 4 always present features, 3 common features.
No clinical trials have been registered for cardiomyopathy, dilated, 2D.
18 publications have been identified in PubMed for cardiomyopathy, dilated, 2D. Research spans Diagnostic / Biomarker (22%), Case Report / Case Series (22%), and Clinical Trial Publication (22%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 4 | 22% |
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Online Mendelian Inheritance in Man
Common questions about cardiomyopathy, dilated, 2D
Lungs and breathing | 1 | High blood pressure in lung arteries (pulmonary arterial hypertension) |
Muscles | 1 | Muscular ventricular septal defect |
Age of onset: infancy.
Patient case studies
4 |
22% |
Clinical study results | 4 | 22% |
Laboratory research | 4 | 22% |
Research summaries | 1 | 6% |
Disease patterns and progression | 1 | 6% |
Yan C (2026). [PMID: 41896746](https://pubmed.ncbi.nlm.nih.gov/41896746/). *BMC Cardiovasc Disord*. [Diagnostic / Biomarker]
Tulluri U (2026). [PMID: 41536733](https://pubmed.ncbi.nlm.nih.gov/41536733/). *Eur Heart J Case Rep*. [Case Report / Case Series]
Zhang X (2026). [PMID: 40820268](https://pubmed.ncbi.nlm.nih.gov/40820268/). *Am J Med Genet A*. [Case Report / Case Series]
Murphy MR (2026). [PMID: 41495453](https://pubmed.ncbi.nlm.nih.gov/41495453/). *Nat Cardiovasc Res*. [Case Report / Case Series]
AbdelMassih AF (2025). [PMID: 40685374](https://pubmed.ncbi.nlm.nih.gov/40685374/). *BMC Cardiovasc Disord*. [Diagnostic / Biomarker]
Karau B (2025). [PMID: 41177866](https://pubmed.ncbi.nlm.nih.gov/41177866/). *Echo Res Pract*. [Diagnostic / Biomarker]
Gokhan I (2025). [PMID: 40475450](https://pubmed.ncbi.nlm.nih.gov/40475450/). *bioRxiv*. [Basic Science / Preclinical]
Murphy MR (2025). [PMID: 39803500](https://pubmed.ncbi.nlm.nih.gov/39803500/). *bioRxiv*. [Basic Science / Preclinical]
Muntean I (2025). [PMID: 41595574](https://pubmed.ncbi.nlm.nih.gov/41595574/). *Biomedicines*. [Clinical Trial Publication]
Mui D (2025). [PMID: 40841467](https://pubmed.ncbi.nlm.nih.gov/40841467/). *Int J Cardiovasc Imaging*. [Diagnostic / Biomarker]